Synapse CEO announcement

Published : 08/06/2018

Synapse Electroceutical today announced that the Board of Directors has appointed Andy Boyes as Interim Chief Executive Officer. John Gildersleeve will assume the role of Business Development Director and will continue to serve as an executive director on the Board.

John Gildersleeve commented “Strengthening the board and adding industry experience has been something I’ve been determined to achieve during my tenure and I’m tremendously excited that Andy has agreed to take on this role. As we focus on driving commercial adoption in the UK, this is the perfect time for Andy to become Synapse’s next Chief Executive Officer.  The Board have selected a strong, experienced leader, with fantastic sector connections, at a time when there is much change, and equally exciting opportunities, in wound care. Andy’s vision, strategy and execution track record are exactly what Synapse needs as we enter our next chapter”. 

Andy Boyes commented “I joined synapse 6 months ago as Non-Executive Director because I wanted to be a part of a company where I believed my experience and support could make a difference. I believe Accel‑Heal® is a product that has real potential to be a key component in the battle against painful, non-healing leg ulcers. I’m excited to have an even greater involvement in the business in my new leadership role and I’m keen to help progress the business towards achieving some important commercial milestones. I’ve got to know John and Andrew over the last 6 months and know we will make a great working partnership”.

Reid Thurlow, Chairman, added “Since joining Synapse as a Non-Executive Director, Andy Boyes has demonstrated significant industry knowledge and expertise and the Board has recognised the value he can add in an executive role. Andy is passionate about seeking ways to develop and enhance wound management and we are delighted to be able to harness his commercial experience and impressive professional network. It says a lot about the character, unyielding desire and ambition of John Gildersleeve, that he is fully supportive of Andy’s appointment in order to ensure that Synapse has every chance to be successful.  A lot of hard work and challenges lie ahead, but I have total confidence in the executive team and they will continue to have my support for as long as I remain Chairman”.

Please send your comments via Twitter

Information for Patients

Accel-Heal product shot